Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04922385
Other study ID # CBT-SC-Peri
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date March 31, 2023

Study information

Verified date August 2022
Source St. Joseph's Healthcare Hamilton
Contact Sheryl M Green, PhD, CPsych
Phone 905-522-1155
Email sgreen@stjoes.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Given the high rates and associated impairment of sexual concerns during the menopausal transition, and specifically during perimenopause, our team has developed a CBT protocol specifically designed to target these prevalent and distressing sexual concerns. The broad aim of the proposed study is to validate this new protocol in a clinic that provides empirically-supported assessment and intervention services for women with menopause-related symptoms. The primary objective of this study is to evaluate the efficacy of a four-week individual CBT protocol in improving sexual satisfaction and reducing distress during perimenopause. The secondary objective of this study is to evaluate the efficacy of this CBT protocol to improve sexual functioning (e.g., desire, arousal), relationship satisfaction, and body image. Exploratory analyses will examine the impact on this CBT protocol on vasomotor symptoms, depression, and anxiety.


Recruitment information / eligibility

Status Recruiting
Enrollment 62
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: 1. 40-60 years of age; 2. peri-menopausal and have had a menstrual period within the previous twelve months as per the STRAW definition (Harlow et al., 2012); 3. cut-off score of 26 or lower on the Female Sexual Functioning Index, indicating sexual dysfunction (Wiegel et al., 2005); 4. medication stable (e.g., hormone therapy), with no changes in dosing for the previous three months (Green et al., 2019); 5. no psychological treatment to address sexual dysfunction and/or sexual concerns within the previous six months; and 6. speak, read, and write in English to comprehend testing procedures and written materials in treatment 7. living within Canada Exclusion Criteria: 1. participants with psychotic disorders, or current substance and/or alcohol dependence; and 2. participants who are severely depressed/suicidal at time of the intake assessment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cognitive Behavioural Therapy
This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).

Locations

Country Name City State
Canada St. Joseph's Healthcare Hamilton Hamilton Ontario

Sponsors (1)

Lead Sponsor Collaborator
St. Joseph's Healthcare Hamilton

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Female Sexual Desire Questionnaire (FSDQ) The FSDQ (Goldhammer & McCabe, 2011) is a 50-item self-report questionnaire assessing one's experience of and sexual desire for women across six domains: dyadic desire, solitary desire, resistance, positive relationship, sexual self-image, and concern. Total scores range from 50 to 300, with higher scores indicated increased sexual desire. 6 weeks
Primary Female Sexual Distress Scale-Revised (FSDS-R) The FSDS-R (DeRogatis et al., 2008) is a 13-item self-report questionnaire assessing various aspects of sexual distress, with a clinical cut-off score of 11 indicated sexual distress. Scores on the FSDS-R range from 0 to 48, with higher scores indicating greater sexual distress. 6 weeks
Primary The Female Sexual Function Index (FSFI) The FSFI (Rosen et al., 2000) is a six domain measure of female sexual functioning including sexual desire, subjective arousal, lubrication, orgasm, satisfaction, and pain. Scores on the FSFI range from 2-36, which higher scores indicating a greater level of sexual function. 6 weeks
Secondary The Greene Climacteric Scale (GCS) The GCS (Greene, 1998) is a self-report questionnaire measuring four menopause-related domains: vasomotor symptoms, depression and anxiety, physical complaints, and sexual concerns. Studies have shown women who score greater than 12 on the GCS are more likely to be menopausal. 6 weeks
Secondary The Hot Flash Related Daily Interference Scale (HFRDIS) The HFRDIS (Carpenter, 2001) assesses the degree to which vasomotor symptoms interfere with daily life. Higher scores on the HFRDIS indicate higher interference due to hot flashes and thus, greater impact on quality of life. 6 weeks
Secondary The Beck Depression Inventory-II (BDI-II) The BDI-II (Beck et al., 1996) is a self-report questionnaire and one of the most widely used tools for measuring depression. Total scores on the BDI-II range from 0-63, with higher scores indicating increased depressive symptom severity. 6 weeks
Secondary The Hamilton Anxiety Scale (HAM-A) The HAM-A (Hamilton, 1959) is a clinician administered questionnaire developed to quantify the severity of anxiety symptomatology and is considered a gold-standard. Total scores on the HAM-A range from 0-56, with greater scores indicating increased anxiety severity. 6 weeks
Secondary The Couples Satisfaction Index (CSI) The CSI (Funk & Rogge, 2007) is a 32-item scale designed to measure one's satisfaction in a relationship. Total scores on the CSI range from 0-81, with higher scores indicating greater couples satisfaction. 6 weeks
Secondary 36-Item Short-Form Health Survey (SF-36) The SF-36 (Ware & Sherbourne, 1992) is a 36-item self-administered questionnaire assessing one's perception of overall health and well-being. Higher scores on each domain indicate a more favourable health state in that area. 6 weeks
Secondary Dresden Body Image Questionnaire (DBIQ) The DBIQ (Scheffers et al., 2017) is a 35-item self-report questionnaire assessing one's feelings of their physical appearance across five subscales: body acceptance, sexual fulfillment, physical contact, vitality, and self-aggrandizement. Higher score on the DBIQ indicate a more positive body image. 6 weeks
Secondary Cognitive Flexibility Inventory (CFI) The CFI (Dennis & Vander Wal, 2010) is a 20-item self-report questionnaire that assesses three aspects of cognitive flexibility: tendency to perceive difficult situations as controllable, ability to perceive multiple alternative explanations for life occurrences and human behaviour, and ability to generate multiple alternative solutions to difficult situations. Higher scores are indicative of greater cognitive flexibility when encountering stressful situations. 6 weeks
See also
  Status Clinical Trial Phase
Unknown status NCT02423694 - Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression N/A
Completed NCT01933204 - Acupuncture for Relieving Perimenopausal Symptoms Phase 2/Phase 3
Recruiting NCT03505905 - A Neurosteroid Intervention for Menopausal and Perimenopausal Depression Phase 1/Phase 2
Completed NCT01308814 - Perimenopausal Estrogen Replacement Therapy Study Phase 2/Phase 3
Recruiting NCT04255160 - Impact of Estradiol on Endothelial Function in Peri-Menopausal Women Phase 4
Completed NCT00471731 - Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure N/A
Not yet recruiting NCT06376812 - No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women N/A
Completed NCT02779582 - Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow Phase 3
Completed NCT05234814 - Fire Dragon Pot Moxibustion N/A
Completed NCT06018740 - A Study to Examine the Effects of a Daily Supplement on Common Symptoms of Perimenopause and Menopause N/A
Recruiting NCT01414530 - Oral Contraceptive During Menopausal Transition N/A
Recruiting NCT01325389 - Myo-inositol Plus Melatonin in Perimenopausal Women N/A